Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) just unveiled an announcement.
TOT BIOPHARM International Co. Ltd. has announced the details of its upcoming annual general meeting, scheduled for June 20, 2025. The meeting will address several key resolutions, including the approval of the company’s financial statements for 2024, the re-election of board members, and the reappointment of PricewaterhouseCoopers as auditors. Additionally, the meeting will consider authorizing the board to manage the company’s share capital, which could impact the company’s financial strategy and shareholder value.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. is a company incorporated in Hong Kong, operating in the biopharmaceutical industry. It focuses on the development, manufacturing, and commercialization of oncology drugs, aiming to provide innovative treatments for cancer patients.
Average Trading Volume: 165,256
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.39B
For an in-depth examination of 1875 stock, go to TipRanks’ Stock Analysis page.